A deficiency in CCR2 monocytes: the hidden side of Alzheimers disease

Alzheimers disease (AD) is a neurodegenerative disorder characterized by intracellular neurofibrillary tangle formation and extracellular amyloid- (A) deposition. To date, microglia seem to act as double-edged swords, being either beneficial (e.g. clearance of A) or detrimental (e.g. secretion of neurotoxic factors) in AD. Following a rather intense debate on the question, a consensus has emerged that microglia can renew themselves via proliferation of already differentiated microglia as well as via the de novo recruitment of monocytes of mouse models of AD. However, recent advances suggest distinct function for resident and bone marrow-derived microglia (BMDM), and have emphasized the neuroprotective functions of BMDM. BMDM is the only subset of cells that restrict cerebral amyloidosis in the AD brain, which has been recently attributed to CCR2 monocytes. Moreover, an impaired recruitment of CCR2 monocytes has been reported in AD patients, as seen from the CCR2 monocytopenia found in the bloodstream and BM. The present review summarizes the current knowledge on the roles and dysfunctions of CCR2 monocytes in AD and their potential as key therapeutic targets.